Raymond James Starts AptarGroup (ATR) at Outperform

Raymond James analyst Matt Roberts initiates coverage on AptarGroup (NYSE: ATR) with a Outperform rating and a price target of $200.00.

The analyst comments "We initiate coverage of AptarGroup (ATR) with an Outperform rating and introduce a $200 price target. In our view, Aptar’s defensible moats and fortress balance sheet, coupled with a specialty and growing position in Pharma end markets, make it a high quality compounder story long term. Near term, we acknowledge risk related to outsized international exposure and potentially lingering headwinds in Beauty — the latter of which we expect to mostly resolve in 2H25. Nonetheless, as the mix shift story continues, driven by Aptar’s highest-margin Proprietary Drug Delivery Systems and an inflection in higher-value injectables components, we expect both margin and ROIC expansion alike, which is further supported by strict adherence to cost and renewed innovation rigor in Beauty/Closures. Based on our sum-of-the-parts (SOTP) analysis, we believe investor appreciation for the sizable Pharma mix shift and exposure to areas of higher growth is still in the “early innings,” and lest we overuse baseball terminology..."

For an analyst ratings summary and ratings history on AptarGroup click here. For more ratings news on AptarGroup click here.

Shares of AptarGroup closed at $155.50 yesterday.

You May Also Be Interested In